Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients

Arthritis and Rheumatism

Volumn 52, Issue 7, 2005, Pages 2060-2068

  Calvo Alén, Jaime ^a   Toloza, Sergio M A ^a   Fernández, Mónica ^a   Bastian, Holly M ^a   Fessler, Barri J ^a   Roseman, Jeffrey M ^a   McGwin Jr , Gerald ^a   Vilá, Luis M ^b   Reveille, John D ^c   Alarcón, Graciela S ^a,d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF PUERTO RICO MEDICAL SCIENCES CAMPUS   (Puerto Rico)

^c UNIVERSITY OF TEXAS   (United States)

^d 830 Faculty Office Tower ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PREDNISONE; TRIACYLGLYCEROL;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOSE RESPONSE; FEMALE; HISPANIC; HUMAN; LIPOPROTEIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VEIN THROMBOSIS;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AGING; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RISK FACTORS; SMOKING; UNITED STATES; VENOUS THROMBOSIS;

EID: 22244470734     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21149     Document Type: Article

References (54)

1. Cervera R. Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999;78:167-75.
2. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002;29:2531-6.
3. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998;7:15-22.
4. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus: a meta-analysis. Lupus 1997;6:467-73.
5. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
6. Petri M, Rheinschmidt M, Whiting-O'Keefe Q, Hellmann D, Corash L. The frequency of lupus anticoagulant in systemic lupus erythematosus: a study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. Ann Intern Med 1987;106:524-31.
7. Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999;8:197-209.
8. Alarcon GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, Goel N, et al. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
11. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998;41:1161-72.
12. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32: 1107-18.
13. Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
14. Harris EN. The second international anti-cardiolipin standardization workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) Group. Am J Clin Pathol 1990;94:476-84.
15. Roisin JP, Contant G, Martinoli JL. Detection of lupus-like anticoagulants (LA): use of hexagonal phosphatidylethanolamine and of an APTT reagent sensitive to LA. Thromb Haemost 1991;65:2023.
16. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993;70:787-93.
17. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995;102:174-80.
18. Costenbader KH, Kim DJ, Peerzada J, Lockman S, Nobles-Knight D, Petri M, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. Arthritis Rheum 2004;50:849-57.
19. Formica MK, Palmer JR, Rosenberg L, McAlindon TE. Smoking, alcohol consumption, and risk of systemic lupus erythematosus in the Black Women's Health Study. J Rheumatol 2003;30:1222-6.
20. Ghaussy NO, Sibbitt WJ, Qualls CR. Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus: a case-control study. J Rheumatol 2001;28:2449-53.
21. Hardy CJ, Palmer BP, Muir KR, Sutton AJ, Powell RJ. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 1998;57:451-5.
22. Ghaussy NO, Sibbitt WJ, Bankhurst AD, Quails CR. Cigarette smoking and disease activity in systemic lupus erythematosus. J Rheumatol 2003;30:1215-21.
23. Ward MM, Studenski S. Clinical prognostic factors in lupus nephritis. Arch Intern Med 1992;152:2082-8.
24. Petri M. Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus [abstract]. Arthritis Rheum 1997;40 Suppl 9:S118.
25. Brown K, Petri M, Goldman D. Cutaneous manifestations of SLE: associations with other manifestations of SLE and with smoking [abstract]. Arthritis Rheum 1995;38 Suppl 6:R27.
26. Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998;25:1716-9.
27. Jay SJ. Cigarette smoking: risk factor for venous thromboembolic disease? Arch Intern Med 1998;158:2315-23.
28. Kahn SR. The clinical diagnosis of deep venous thrombosis: integrating incidence, risk factors, and symptoms and signs. Arch Intern Med 1998;158:2315-23.
29. Pollock AV, Evans M. Cigarette smoking and postoperative deep-vein thrombosis. Br Med J 1978;2:637.
30. Clayton JK, Anderson JA, McNicol GP. Effect of cigarette smoking on subsequent postoperative thromboembolic disease in gynaecological patients. Br Med J 1978;2:402.
31. Baglin T. Is smoking a risk factor for venous thromboembolism? Thromb Haemost 2002;88:881-2.
32. Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, et al. A prospective study of risk factors for venous thromboembolism among middle-aged men: the study of men born in 1913. J Am Med Assoc 1997;277:642-5.
33. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: the study of men born in 1913. Arch Intern Med 1999;159:1886-90.
34. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549-53.
35. Doria A, Shoenfeld Y, Wu R, Gambari PF, Puato M, Ghirardello A, et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003;62:1071-7.
36. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
37. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
38. Petri M, Roubenoff R, Dallai G, Nadeau MR, Selhub J, Rosenbert IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
39. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994;70: 863-70.
40. Wadman B, Werner I. Thromboembolic complications during corticosteroid treatment of temporal arteritis. Lancet 1972;1:907.
41. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000;23: 145-50.
42. Boscaro M, Nicoletta S, Scarda A, Barzon L, Fallo F, Sartori M, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 2002;87:3662-6.
43. Dal Bo Zanon R, Fornasiero L, Boscaro M, Ruffato G, Luzzato G, Fabris F, et al. Clotting changes in Cushing's syndrome: elevated factor VIII activity. Folia Haemotal Int Mag Klin Morphol Blutforsch 1983;110:268-77.
44. Ueda N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 1990;56:374-8.
45. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002;46:1019-27.
46. Amigo MC, Khamashta MA, Hughes GR. Antiphospholipid syndrome in SLE. Baillieres Clin Rheumatol 1998;12:477-93.
47. Khamashta MA, Hughes GR. Antiphospholipid antibodies and antiphospholipid syndrome. Curr Opin Rheumatol 1995;7:389-94.
48. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57.
49. Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. J Rheumatol. In press.
50. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH. Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117: 997-1002.
51. Sairam S, Baethge BA, McNearney T. Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies. Clin Rheumatol 2003;22: 24-9.
52. Fernandez M, Calvo-Alen J, Bertoli AM, Vila LM, Fessler B, Bastian H, et al. Hormone replacement therapy is not a risk factor for vascular arterial events in systemic lupus erythematosus and it does not negatively impact on disease activity: data from a large multi-ethnic cohort [abstract]. Lupus 2005;14:220.
53. Fernandez M, Calvo-Alen J, Alarcon GS, Roseman JM, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum 2005;52:1655-64.
54. Hudson M, Herr AL, Rauch J, Neville C, Chang E, Ibrahim R, et al. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 2003;30:2385-91.